Sf-RVN® Insect Cell Line (Sf9-derived, Rhabdovirus-Negative)

Overview

The Sf-RVN® Insect Cell Line is a rigorously characterized, rhabdovirus-negative derivative of the Spodoptera frugiperda (Sf9) cell line, engineered for robust performance in both adherent and suspension culture systems. It serves as a foundational host system for the production of complex biologics—including recombinant proteins, adeno-associated viruses (AAVs), and virus-like particles (VLPs)—within chemically defined, animal-component-free environments. Unlike conventional Sf9 lines, Sf-RVN® undergoes comprehensive exogenous agent testing under current Good Manufacturing Practice (cGMP)-aligned conditions to eliminate known adventitious viral contaminants—most critically, rhabdoviruses such as Vesicular Stomatitis Virus (VSV), which pose significant safety and regulatory risks in upstream bioprocessing. Its adaptation to serum-free, chemically defined EX-CELL® CD Insect Medium enables scalable, reproducible expansion while maintaining high transfection efficiency and post-translational fidelity essential for functional protein expression.

Key Features

• Rhabdovirus-negative status confirmed by PCR, in vitro infectivity assays, and electron microscopy—critical for biosafety assurance in GMP-aligned workflows
• Fully adapted to suspension growth in EX-CELL® CD Insect Medium, supporting high-density cultures (>5 × 10⁶ cells/mL) with consistent viability (>95%) over multiple passages
• cGMP-compliant external agent testing performed per ICH Q5A(R2) and USP <1046> guidelines, including tests for mycoplasma, bacteria, fungi, and a broad panel of insect-specific viruses
• Supplied cryopreserved at 10 × 10⁶ cells/mL in 1 mL vials, formulated in EX-CELL® CD Insect Medium supplemented with 10% DMSO for optimal recovery and minimal post-thaw lag phase
• Accompanied by full traceability documentation: Certificate of Analysis (CoA), Certificate of Origin, Master Cell Bank (MCB) characterization report, and detailed handling protocols compliant with ISO 9001 and ISO/IEC 17025 quality frameworks

Sample Compatibility & Compliance

Sf-RVN® is validated for use with baculovirus expression vector systems (BEVS), transient transfection reagents optimized for insect cells (e.g., Cellfectin II, FuGENE HD), and stable integration platforms. It supports high-titer AAV production when co-transfected with helper plasmids and AAV rep/cap constructs. All lot-specific testing adheres to internationally recognized standards: ISO 9001 for quality management, ISO/IEC 17025 for testing competence, and alignment with FDA guidance on cell substrate characterization (ICH Q5D). While intended for research use only (RUO), the cell line’s cGMP-aligned documentation package facilitates early-stage regulatory submissions—including IND-enabling studies—and streamlines technology transfer to contract development and manufacturing organizations (CDMOs).

Software & Data Management

No proprietary software is required for routine culture or assay execution. However, Merck provides digital access to standardized SOPs, thaw-to-harvest timelines, and QC release data via secure customer portals compliant with 21 CFR Part 11 requirements for electronic records and signatures. Batch-specific CoAs are digitally signed and timestamped, with audit trails retained for ≥15 years. Integration with laboratory information management systems (LIMS) is supported through structured CSV and PDF exports containing metadata fields aligned with ISA-Tab standards for reproducible experimental annotation.

Applications

• High-yield production of glycosylated and multimeric recombinant proteins requiring insect-specific post-translational modifications
• Scalable AAV vector manufacturing for preclinical and clinical gene therapy programs
• VLP assembly for vaccine development (e.g., HPV, HBV, norovirus) and structural immunology studies
• Functional screening of baculovirus promoters, enhancer elements, and codon-optimized transgenes
• Comparative virology studies requiring rhabdovirus-free backgrounds to avoid confounding cytopathic effects

FAQ

Is Sf-RVN® suitable for GMP manufacturing?
Sf-RVN® is supplied under RUO terms and is not licensed for commercial manufacturing. Its cGMP-aligned testing and documentation support process validation and regulatory filing, but formal licensing must be obtained directly from Merck prior to clinical or commercial use.
What medium is recommended for optimal performance?
EX-CELL® CD Insect Medium is the only chemically defined, serum-free formulation validated for Sf-RVN® expansion and expression—enabling consistent growth kinetics and reduced lot-to-lot variability.
How is cell identity confirmed?
Identity is verified via STR profiling against reference Sf9 databases and species-specific mitochondrial DNA sequencing, with results included in each CoA.
Can Sf-RVN® be adapted to other media formulations?
While possible, adaptation may compromise rhabdovirus-negative status verification and reduce expression consistency; Merck does not support or validate alternative media.
What documentation accompanies each vial?
Each shipment includes a CoA, Certificate of Origin, MCB characterization summary, cryopreservation protocol, and a technical user guide with passaging, transfection, and harvest optimization strategies.